FI115302B - Tri-substituerade fenylderivat användbara som PDE IV -inhibitorer - Google Patents

Tri-substituerade fenylderivat användbara som PDE IV -inhibitorer Download PDF

Info

Publication number
FI115302B
FI115302B FI965126A FI965126A FI115302B FI 115302 B FI115302 B FI 115302B FI 965126 A FI965126 A FI 965126A FI 965126 A FI965126 A FI 965126A FI 115302 B FI115302 B FI 115302B
Authority
FI
Finland
Prior art keywords
group
formula
pyridine
cyclopentyloxy
compound
Prior art date
Application number
FI965126A
Other languages
English (en)
Finnish (fi)
Other versions
FI965126A (sv
FI965126A0 (sv
Inventor
Graham John Warrellow
Rikki Peter Alexander
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9412385A external-priority patent/GB9412385D0/en
Priority claimed from GB9412492A external-priority patent/GB9412492D0/en
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Publication of FI965126A publication Critical patent/FI965126A/sv
Publication of FI965126A0 publication Critical patent/FI965126A0/sv
Application granted granted Critical
Publication of FI115302B publication Critical patent/FI115302B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Lock And Its Accessories (AREA)

Claims (6)

1. Förening med formeln (1') RO v RaO-/\-2 (1' ) 5 väri R är Ci_4-alkyl, Ci-4-halogenalkyl eller C3-8-cykloalkyl; Ra är en väteatom, Ci_4-alkyl eller Ci-4-halogen-10 alkyl och Z är grupp (A) eller (B) H H n4 vkl· w % R4 R5 X \R5 (A) (B) . 15 » · » · A van R är en väteatom eller grupp -(CH2)tAr eller » · • - (CH2) tAr (Alk4) x (0) y (Alk5) zArväri Ar och Ar' vardera be-* * · * tecknar en fenylgrupp, som eventuellt är substituerad med : i en substituent som har valts frän Ci-4-alkyl, trifluorme- 20 tyl, nitro, amino, Ci-4-alkylkarbonylamino, Ci-4-alkylsulfo-nylamino och di (Ci-4-alkyl) aminosulfonylamino; Alk4 och Alk5 betecknar vardera en Ci_4-alkylen-grupp, som eventuellt är substituerad med halogen eller hydroxi; t är noll eller ett heltal 1, 2 eller 3 och x, y * 25 och z är oberoende av varandra 0 eller 1; och t * · c ‘I R är pyridyl, som eventuellt är substituerad med fenyl-Ci-4-alkyl; och dess f armaceutiskt godtagbara salter, solva-ter, hydrater och N-oxider. t 30 115302 51
2. Förening enligt patentkrav 1, väri Z är grupp (A) .
3. Förening enligt patentkrav 1 eller 2, väri R5 är en eventuellt substituerad 4-pyridylgrupp. 5
4. Förening enligt patentkrav 1, väri Z är grupp (B) och R4 är en väteatom.
5. Förening, kännetecknad av att den är: (±)—4—{2—(3-cyklopentyloxi-4-metoxifenyl)-2-[4-(4-trifluormetylfenyl)fenyletyl]}pyridin; 10 (±)-4-[2-(4-bensyloxifenyl)-2-(3-cyklopentyloxi-4- metoxifenyl)etyl]pyridin; (±)-4-{2-(3-cyklopentyloxi-4-metoxifenyl)-2-[4—(4— nitrotenyloxi)fenyl]etyl}pyridin; (E)- och (Z)-isomerer av 4-[2-(3-cyklopentyloxi-4-15 metoxifenyl)etenyl]-3-(fenyletyl)pyridin; (±)-4-[2-(3-cyklopentyloxi-4-metoxifenyl)etyl]-3-(fenyletyl)pyridin; (±)—4 — {2 —[4-(4-aminofenyloxi)fenyl]-2-(3-cyklopen-tyloxi-4-metoxifenyl)etyl]}pyridin; 20 (±)—4—{2—[4-(4-acetamidofenyloxi)fenyl]-2-(3-cyk- lopentyloxi-4-metoxifenyl)etyl]}pyridin; (±) —4 — {2— (3-cyklopentyloxi-4-metoxifenyl) -2- [4-(4->,· N', N'-dimetylaminosulfonylaminofenyl) fenyloxi] etyljpyri- din; t 25 (±)—4 —{2—(3-cyklopentyloxi-4-metoxifenyl)-2-[4-(4- metylsulfonylaminofenyl)fenyloxi]etylJpyridin; I (±)-4-[2-(3-cyklopentyloxi-4-metoxifenyl)-2-(4'- * metyl-4-bifenyl)etyl]pyridin; och dess enskilda isomerer, separerade enantiome- I I : · 30 rer, salter, solvater, hydrater och N-oxider.
.,* 6. Farmaceutisk komposition, som innehäller en fö- *j rening enligt nägot av de föregaende patentkraven och en > eller flera farmaceutiskt godtagbara bärare, utdrygnings-·_ medel eller utspädningsmedel.
FI965126A 1994-06-21 1996-12-19 Tri-substituerade fenylderivat användbara som PDE IV -inhibitorer FI115302B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9412385A GB9412385D0 (en) 1994-06-21 1994-06-21 Chemical compounds
GB9412385 1994-06-21
GB9412492A GB9412492D0 (en) 1994-06-22 1994-06-22 Chemical compounds
GB9412492 1994-06-22
PCT/GB1995/001459 WO1995035281A1 (en) 1994-06-21 1995-06-21 Tri-substituted phenyl derivates useful as pde iv inhibitors
GB9501459 1995-06-21

Publications (3)

Publication Number Publication Date
FI965126A FI965126A (sv) 1996-12-19
FI965126A0 FI965126A0 (sv) 1996-12-19
FI115302B true FI115302B (sv) 2005-04-15

Family

ID=26305090

Family Applications (1)

Application Number Title Priority Date Filing Date
FI965126A FI115302B (sv) 1994-06-21 1996-12-19 Tri-substituerade fenylderivat användbara som PDE IV -inhibitorer

Country Status (18)

Country Link
US (2) US5786354A (sv)
EP (1) EP0770065B1 (sv)
JP (1) JP3856465B2 (sv)
CN (1) CN1304372C (sv)
AT (1) ATE263153T1 (sv)
AU (1) AU707472B2 (sv)
CZ (1) CZ293311B6 (sv)
DE (1) DE69532808T2 (sv)
DK (1) DK0770065T3 (sv)
ES (1) ES2218548T3 (sv)
FI (1) FI115302B (sv)
HU (1) HUT76803A (sv)
NO (1) NO312672B1 (sv)
NZ (1) NZ288294A (sv)
PT (1) PT770065E (sv)
RU (1) RU2201921C2 (sv)
SK (1) SK282661B6 (sv)
WO (1) WO1995035281A1 (sv)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
DE69433594T2 (de) * 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CA2238875C (en) * 1995-12-15 2003-09-16 Merck Frosst Canada Inc. Tri-aryl ethane derivatives as pde iv inhibitors
US5710170A (en) * 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
DE19605766A1 (de) * 1996-02-16 1997-08-21 Basf Ag Substituierte 2-Phenylpyridine
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US6180650B1 (en) * 1999-04-23 2001-01-30 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE60043318D1 (de) 1999-08-21 2010-01-14 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6410563B1 (en) 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6639077B2 (en) 2000-03-23 2003-10-28 Merck Frosst Canada & Co. Tri-aryl-substituted-ethane PDE4 inhibitors
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
CA2407780A1 (en) 2000-05-25 2001-11-29 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
US6740666B2 (en) 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) * 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
ES2247325T3 (es) 2001-05-24 2006-03-01 MERCK FROSST CANADA & CO. Inhibidores de 1-biaril-1,8-naftiridin-4-ona fosfodiesterasa-4.
WO2002096888A1 (de) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
DE10150517A1 (de) * 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
CN100381425C (zh) * 2002-07-19 2008-04-16 记忆药物公司 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑及其药物组合物和用途
MXPA05000827A (es) 2002-07-19 2005-08-29 Memory Pharm Corp Inhibidores de fosfodiesterasa 4, incluyendo analogos de anilina y difenilamina n-sustituidos.
CN100513397C (zh) * 2002-11-19 2009-07-15 记忆药物公司 磷酸二酯酶4抑制剂
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR20050115331A (ko) 2003-04-01 2005-12-07 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 불임증 포스포디에스터라제의 억제제
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
AU2005295788A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008006509A1 (en) * 2006-07-14 2008-01-17 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
CN106946848B (zh) 2011-06-06 2022-01-04 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
CN103827088B (zh) 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
WO2013057013A2 (en) 2011-10-21 2013-04-25 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
BR112014029642A2 (pt) 2012-06-04 2017-06-27 Chiesi Farm Spa composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
PL2928869T3 (pl) 2012-12-05 2019-08-30 Chiesi Farmaceutici S.P.A. Pochodne alkoholu 1-fenylo-2-pirydynyloalkilowego jako inhibitory fosfodiesterazy
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1285932A (fr) * 1960-12-26 1962-03-02 Nord Aviation Charge creuse
US3947467A (en) * 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
FR2257272B1 (sv) * 1974-01-15 1978-08-25 Pharmascience Labo
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
FR2313422A2 (fr) * 1975-06-02 1976-12-31 Labaz Nouveaux stabilisants des polymeres et copolymeres du chlorure de vinyle
SU888821A3 (ru) * 1976-12-03 1981-12-07 Шеринг Аг (Инофирма) Способ получени 5-(замещенный фенил)-оксазолидинонов или их серусодержащих аналогов
EP0006298B1 (en) * 1978-06-15 1982-03-31 Imperial Chemical Industries Plc Anti-inflammatory 1-phenyl-2-aminoethanol derivatives, pharmaceutical compositions thereof for topical use, and processes for their manufacture
DE3374313D1 (de) * 1982-12-23 1987-12-10 Smith Kline French Lab Aminopyrimidinone derivatives as histamine h1-antagonists
IT1161221B (it) * 1983-04-21 1987-03-18 Ripharm Srl Composto per il trattamento della psoriasi
US4694009A (en) * 1984-06-25 1987-09-15 Ciba-Geigy Corporation Pesticidal compositions
DE3751742T3 (de) * 1986-01-13 2002-11-21 American Cyanamid Co., Wayne 4,5,6-Substituierte 2-Pyrimidinamine
US4876252A (en) * 1986-01-13 1989-10-24 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
US4788195A (en) * 1986-01-13 1988-11-29 American Cyanamid Company 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines
HU215433B (hu) * 1986-04-29 2000-05-28 Pfizer Inc. Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására
US5128358A (en) * 1988-01-19 1992-07-07 Pfizer Inc. Aryl substituted nitrogen heterocyclic antidepressants
US4921862A (en) * 1986-05-29 1990-05-01 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
CN1030415A (zh) * 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
US5274002A (en) * 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
DE3882821D1 (de) * 1987-06-11 1993-09-09 Ciba Geigy Ag Mikrobizide.
US4966622A (en) * 1988-04-12 1990-10-30 Ciba-Geigy Corporation N-phenyl-N-pyrimidin-2-ylureas
US4897396A (en) * 1988-06-03 1990-01-30 Ciba-Geigy Corporation 2-phenylamino pyrimidine derivatives and their uses as microbicides
DE59009351D1 (de) * 1989-04-17 1995-08-03 Byk Gulden Lomberg Chem Fab Neue arylpyridazine, ihre herstellung, verwendung und sie enthaltende arzneimittel.
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH075572B2 (ja) * 1989-08-18 1995-01-25 積水化学工業株式会社 ２―［２―（２―ヒドロキシフェニル）ビニルピラジンおよびその製造法
JPH0377923A (ja) * 1989-08-18 1991-04-03 Sekisui Chem Co Ltd 有機非線形光学材料
DE4003919A1 (de) * 1990-02-09 1991-08-14 Basf Ag Heteroarylalkene, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
WO1991016892A1 (en) * 1990-04-27 1991-11-14 Rorer International (Holdings), Inc. Styryl compounds which inhibit egf receptor protein tyrosine kinase
MC2311A1 (fr) * 1990-07-10 1993-09-27 Smithkline Beecham Corp Oxamides
US5124455A (en) * 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
CA2091989A1 (en) * 1990-09-28 1992-03-29 Roderick Alan Porter Phenylpyridinol derivatives as medicaments
DE59109027D1 (en) * 1990-10-16 1998-08-13 Byk Gulden Lomberg Chem Fab Arylpyridazinone
WO1992007567A1 (en) * 1990-11-06 1992-05-14 Smithkline Beecham Corporation Imidazolidinone compounds
SE470395B (sv) * 1990-12-05 1994-02-14 Erik Lindgren Produktide Ab Ryggstödjande anordning
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
IE71647B1 (en) * 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5698711A (en) * 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
EP0510562A1 (de) * 1991-04-26 1992-10-28 Byk Gulden Lomberg Chemische Fabrik GmbH Neue Pyridazine
US5191084A (en) * 1991-05-01 1993-03-02 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
EP0540165A1 (en) * 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
DE4136921A1 (de) * 1991-11-11 1993-05-13 Knoll Ag Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure
US5326898A (en) * 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
DE69328778T2 (de) * 1992-04-02 2000-11-23 Smithkline Beecham Corp., Philadelphia Verbindungen für die behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (sv) * 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9212693D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
JP3775684B2 (ja) * 1992-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
JP3100984B2 (ja) * 1992-12-02 2000-10-23 ファイザー・インク． 選択的ｐｄｅ▲下ｉ▼▲下ｖ▼阻害物質としてのカテコールジエーテル類
EP0959074A3 (en) * 1992-12-17 2000-06-07 Pfizer Inc. Substituted pyrazoles as CRF antagonists
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
TW263495B (sv) * 1992-12-23 1995-11-21 Celltech Ltd
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9315595D0 (en) * 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
NZ273617A (en) * 1993-10-01 1996-11-26 Ciba Geigy Ag N-phenyl-2-pyrimidineamine derivatives pharmaceutical compositions
US5612340A (en) * 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
DE69434721T2 (de) * 1993-10-01 2006-11-09 Novartis Ag Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
PL314605A1 (en) * 1993-11-26 1996-09-16 Pfizer Isoxazolin compounds as anti-inflammatory agents
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
DE69433594T2 (de) * 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
US5691376A (en) * 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
CN1149870A (zh) * 1994-06-06 1997-05-14 辉瑞大药厂 具有促皮质激素释放因子拮抗剂活性的取代的吡唑
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
EP0746619A1 (en) * 1994-12-23 1996-12-11 Celltech Therapeutics Limited Human phosphodiesterase type ivc, and its production and use
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
ATE222892T1 (de) * 1995-10-02 2002-09-15 Hoffmann La Roche Pyrimidinderivate als 5ht2c-rezeptorantagonisten
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds

Also Published As

Publication number Publication date
NO312672B1 (no) 2002-06-17
SK163096A3 (en) 1997-10-08
EP0770065A1 (en) 1997-05-02
DE69532808T2 (de) 2005-01-13
PT770065E (pt) 2004-08-31
DK0770065T3 (da) 2004-07-19
NO965524L (no) 1996-12-20
CN1304372C (zh) 2007-03-14
HU9603578D0 (en) 1997-02-28
NO965524D0 (no) 1996-12-20
ATE263153T1 (de) 2004-04-15
EP0770065B1 (en) 2004-03-31
DE69532808D1 (de) 2004-05-06
JP3856465B2 (ja) 2006-12-13
JPH10503173A (ja) 1998-03-24
US6077854A (en) 2000-06-20
AU707472B2 (en) 1999-07-08
RU2201921C2 (ru) 2003-04-10
WO1995035281A1 (en) 1995-12-28
ES2218548T3 (es) 2004-11-16
US5786354A (en) 1998-07-28
NZ288294A (en) 1999-01-28
FI965126A (sv) 1996-12-19
AU2746195A (en) 1996-01-15
CN1151732A (zh) 1997-06-11
CZ293311B6 (cs) 2004-03-17
HUT76803A (en) 1997-11-28
FI965126A0 (sv) 1996-12-19
CZ373096A3 (en) 1997-08-13
SK282661B6 (sk) 2002-11-06

Similar Documents

Publication Publication Date Title
FI115302B (sv) Tri-substituerade fenylderivat användbara som PDE IV -inhibitorer
US11129828B2 (en) Pyridazinone compounds and their use as DAAO inhibitors
EP0766669B1 (en) Tri-substituted phenyl derivatives useful as pde iv inhibitors
US8779148B2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
AU781141B2 (en) Novel use of phenylheteroalkylamine derivatives
US7005432B2 (en) Substituted imidazol-pyridazine derivatives
JP4948708B2 (ja) 抗菌性化合物
JPH08505158A (ja) ホスホジエステラーゼ阻害剤としての三置換フェニル誘導体およびそれらの製造方法
EP1858852A1 (en) Heteroarylsulfonyl stilbenes as 5-ht2a antagonists
AU738347B2 (en) Substituted 1H-pyridinyl-2-ones as gabaaalpha 2/3 ligands
JP3465825B2 (ja) Ｐｄｅ▲ｉｖ▼阻害剤としてのトリアリールエタン誘導体
EP0270091B1 (en) Imidazole derivatives, processes for the preparation of the same, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments of therapeutic value, and intermediates formed during said processes
NZ323521A (en) Compounds for treating reversible obstructive airway disease or allergic conditions
JP2007509998A (ja) Ｐｐａｒ活性化剤としてのベンズ環付加された化合物
JP5384485B2 (ja) ジ（ヘテロ）アリールシクロヘキサン誘導体、それらの製造、それらの使用及びそれらを含む薬剤組成物
JP2005508382A (ja) アントラニル酸アミド類およびその医薬的使用
US5821245A (en) Use of naphthalene derivatives in treating lung carcinoma
KR100501865B1 (ko) 포스포디에스테라제iv억제제로서유용한삼치환된페닐유도체
US20230150985A1 (en) Inhibitors of antigen presentation by hla-dr
US5929087A (en) Decahydroquinoline-based anti-cholinergic agents
CA2192643C (en) Tri-substituted phenyl derivatives useful as pde iv inhibitors
CZ20003289A3 (cs) Antagonisté receptoru vitronektinu

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115302

Country of ref document: FI